| 1. |
Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med, 2010, 7(4): e1000267.
|
| 2. |
Heinrich S, Lang H. Neoadjuvant therapy of pancreatic cancer: definitions and benefits. Int J Mol Sci, 2017, 18(8): 1622.
|
| 3. |
Tempero MA, Malafa MP, Al-Hawary M, et al . Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
|
| 4. |
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol, 2013, 20(12): 3794-3801.
|
| 5. |
Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer, 2016, 62: 132-137.
|
| 6. |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.
|
| 7. |
Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol, 2013, 31(13): 1640-1648.
|
| 8. |
Lazzaro C, Barone C, Caprioni F, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(4): 435-446.
|
| 9. |
Yu KH, Ricigliano M, Hidalgo M, et al. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res, 2014, 20(20): 5281-5289.
|
| 10. |
Torres C, Perales S, Alejandre MJ, et al. Serum cytokine profile in patients with pancreatic cancer. Pancreas, 2014, 43(7): 1042-1049.
|
| 11. |
Kruger S, Heinemann V, Ross C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol, 2018, 29(12): 2348-2355.
|
| 12. |
Dhayat S, Mardin WA, Mees ST, et al. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—a review. Int J Cancer, 2011, 129(5): 1031-1041.
|
| 13. |
Funamizu N, Lacy CR, Kamada M, et al. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Int J Oncol, 2019, 54(3): 991-1000.
|
| 14. |
Baliyan V, Kordbacheh H, Parakh A, et al. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol (NY), 2018, 43(2): 435-444.
|
| 15. |
Pai RK, Pai RK. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. Mod Pathol, 2018, 31(1): 4-23.
|
| 16. |
Boone BA, Steve J, Zenati MS, et al. Serum CA19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol, 2014, 21(13): 4351-4358.
|
| 17. |
álvarez R, Alés I, Díaz R, et al. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Clin Transl Oncol, 2017, 19(10): 1193-1198.
|
| 18. |
Okada K, Kawai M, Hirono S, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol, 2016, 78(4): 719-726.
|
1/5
WeChat